Barron’s Top Weekend Stock Picks: Apple, Disney, Pfizer And Tesla’s Price Cuts Are Leading To Growth
Benzinga reviews this weekend's top stories covered by Barron's, here are the articles investors need to read.
Bulls And Bears Of The Week: Tesla, Meta, Apple, Snap And A Meme Coin Inspired By Musk’s Dog Up 200% In January
Benzinga examined the prospects for many investors' favorite stocks over the last week — here's a look at some of our top stories.
Gilead Sciences’ Trovelvy Scores FDA Approval For Advanced/Metastatic Breast Cancer Setting
The FDA has approved Gilead Sciences Inc’s (NASDAQ:GILD) Trodelvy (sacituzumab govitecan-hziy) for adult patients with advanced or metastatic breast cancer. The…
Why Personalis Shares Are Trading Higher Today
Personalis Inc (NASDAQ:PSNL) and Moderna Inc (NASDAQ:MRNA) have signed a new agreement to continue using the Personalis NeXT Platform as part of upcoming…
Regeneron Pharmaceuticals Q4 Earnings: Revenue Falls As COVID-19-Related Sales Dwindle
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) earned $12.56 per share for Q4 FY22, down 46% Y/Y, beating the $10.03 Street estimate. Revenues…
Sanofi Expects Moderate 2023 Profit Growth On Dupixent Demand, But Dampened By Aubagio Generics Competition
Sanofi SA (NASDAQ:SNY) forecasts 2023 adjusted earnings per share to grow by a “low single-digit” percentage, not considering an expected negative…
Big Tech Calls From Apple, Amazon, Alphabet Paint ‘Different Picture’ Than What Tech Bears Hoped For Says, Wedbush Analyst
Wedbush analyst Dan Ives said Thursday that calls from Apple Inc (NASDAQ: AAPL), Amazon.com, Inc (NASDAQ: AMZN) and Google parent Alphabet Inc (NASDAQ:
Johnson & Johnson’s Upcoming Lung Cancer Data Could Offer Another Blockbuster Opportunity, Says Analyst
Cantor Fitzgerald is previewing its thoughts on a potential interim analysis for Johnson & Johnson’s (NYSE:JNJ) Phase 3 MARIPOSA study of Rybrevant (amivantamab)…
Eli Lilly Posts Weaker Q4 Sales On Slower Demand For Its COVID-19 Treatment, Overshadowing Annual Guidance
Eli Lilly And Co (NYSE:LLY) has reported Q4 sales of $7.30 billion, down 9% Y/Y, missing the consensus of $7.33…
Merck Beats On Q4 earnings, Anticipates Almost 80% Decline In COVID-19 Treatment Sales In 2023
Merck & Co Inc’s (NYSE:MRK) Q4 sales reached $13.8 billion, +2% Y/Y, beating the consensus of $13.67 billion. Excluding the…